Transce3nd’s Myriad Genetics MYGN Stock Holding History

Transce3nd’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10	Closed	-$137	–	1437
2024 Q4	$137	Buy	+10	New	+$185	﹤0.01%	1496

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Transce3nd's MYGN Position: Q1 2025 in Review

Transce3nd sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 10 shares — an estimated $137 sold.

Transce3nd first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $137 in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Transce3nd reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 10 Myriad Genetics shares in Q1 2025, an estimated $137.
Transce3nd first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
Transce3nd's Myriad Genetics position peaked at $137 in Q4 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.